Meld Valuation / Venture NAV Tracker
FundsCompaniesMethodology
meldvaluation.com ↗

Venture NAV Tracker / Private company

Phathom Pharmaceuticals, Inc.

Drug Discovery & Development
Headquarters—
Founded—
Last known round—
Reported valuation—

+972.8% equity-mark dispersion. Hercules Capital, Inc. carries Phathom Pharmaceuticals, Inc. at $1.04/share; Hercules Capital, Inc. carries it at $11.11/share. Review dates and security types before treating those marks as directly comparable.

Cross-fund comparison

Equity & warrant marks

One latest disclosed mark per fund.

FundFair valueSecurity / basisImplied price / shareMark age vs roundMethodology / filing
HTGCHercules Capital, Inc.$1.6MMar 31, 2026 · source ↗equityFair Value$11.11Not comparable — different security type or share classMar 31, 2026 · source ↗—Mar 31, 2026 · source ↗10-Q 2026-03-31 ↗
HTGCHercules Capital, Inc.$67KMar 31, 2026 · source ↗warrantFair Value$1.04Not comparable — different security type or share classMar 31, 2026 · source ↗—Mar 31, 2026 · source ↗10-Q 2026-03-31 ↗

Cross-fund comparison

Debt investments

One latest disclosed debt mark per fund.

FundSecurity type / basisPrincipalFair valueFV / principalRateMaturityMark age vs roundNon-accrual
HTGCHercules Capital, Inc.senior secured loanFair Value — Senior Secured$133.1MMar 31, 2026 · source ↗$132.5MMar 31, 2026 · source ↗99.5%Mar 31, 2026 · source ↗Prime + 3.10 %, Floor rate 9.85 %, 2.00 % Exit FeeMar 31, 2026 · source ↗Feb 1, 2029Mar 31, 2026 · source ↗—Mar 31, 2026 · source ↗NoMar 31, 2026 · source ↗

Historical marks

Reported fair value by fund

Each bar is a disclosed position-quarter.

$132.5MHTGCMar 31, 2026 · source ↗$1.6MHTGCMar 31, 2026 · source ↗$67KHTGCMar 31, 2026 · source ↗
Figures are compiled from public filings.Read methodologyMELD Valuation